NCT02650596

Effects of GLP-1 on Chronic Heart Failure

Effects of Liraglutide on Left Ventricular Function in Chronic Heart Failure Patients With Type 2 Diabetes

• Status: Unknown
• Phase: N/A
• Study type: Interventional
• Enrollment: 68 (estimated)
• Sponsor: Shi Yang · Academic / Other
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

The investigators planned to evaluate the effects of liraglutide on left ventricular function in chronic heart failure patients with type 2 diabetes.

Detailed description

Heart failure (HF) is a major cause of morbidity and mortality world wide. Glucagon-like peptide-1 (GLP-1) is an incretin hormone that regulates plasma glucose, and has direct effects on the cardiovascular system. In our previous study, the GLP-1 analogue liraglutide could improve left ventricular function in patients with acute myocardial infarction. However, the effects of GLP-1 on chronic heart failure patients with type 2 diabetes remain unclear. The aim of this study was to evaluate the effects of liraglutide on left ventricular function in chronic heart failure patients with type 2 diabetes.

Conditions

• Heart Failure

Interventions

Type	Name	Description
DRUG	GLP-1	Liraglutide were taken daily for 3 months
DRUG	Placebo	Placebo were taken daily for 3 months

Timeline

• Start date: 2016-01-01
• Primary completion: 2018-02-01
• Completion: 2018-02-01
• First posted: 2016-01-08
• Last updated: 2016-01-08

Locations

1 site across 1 country: China